Colorectal cancer is the second leading cause of cancer death in Canada ( 1 ) , affecting men and women in equal numbers. In Canada, it has been estimated that 21 500 new cases of colorectal cancer would be diagnosed in 2008, and 8900 deaths from this disease would occur ( 1 ) . Although substantial advances have been made in the management of colorectal cancer, the prognosis remains poor for patients with advanced disease and treatment for these patients is limited to supportive care options.
Several randomized trials have demonstrated that therapy with cetuximab, a monoclonal antibody inhibitor of the epidermal growth factor receptor (EGFR) ( 2 ) , improves a variety of clinically important outcomes in patients with advanced colorectal cancer ( 3 -5 ) . Post hoc exploratory analyses of these studies have suggested that the benefi ts of cetuximab are limited to patients whose tumors harbor a wild-type KRAS gene ( 6 -8 ) . The presence of activating mutations in KRAS , which encodes a G protein essential in downstream signaling of the EGFR pathway, appears to allow tumor cells to proliferate in the presence of cetuximab inhibition of EGFR ( 8 -17 ) .
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) CO.17 (hereafter called CO.17; ClinicalTrials. gov identifi er: NCT00079066) was a multicenter (Canada and Australia), open-label, randomized phase III trial of cetuximab plus best supportive care vs best supportive care alone in patients with chemotherapy-refractory metastatic EGFRpositive colorectal cancer. CO.17 demonstrated a clinically and statistically signifi cant overall survival advantage for cetuximab in this population of patients with metastatic disease (median survival for cetuximab vs best supportive care: 6.1 months [0.51 years] vs 4.6 months [0.38 years] , hazard ratio [HR] for death = 0.77, P = .005) ( 4 ) . The survival advantage was even greater in the subset of patients with wild-type KRAS tumors (median overall survival for cetuximab vs best supportive care: 9.5 months [0.79 years] vs 4.8 months [0.4 years] , HR for death = 0.55, P < .001) ( 7 ) .
Despite these benefi ts, targeted therapies such as cetuximab are likely to increase the already substantial economic burden associated with the management of colorectal cancer. The evaluation of the cost-effectiveness and cost utility of target therapies is of substantial interest to health-care providers, policy makers, and funders. Here, we report the incremental cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year [QALY] gained) of cetuximab plus best supportive care vs best supportive care alone, from the perspective of the Canadian health-care system, for the entire CO.17 study population and for the study participants whose tumors harbored wild-type KRAS .
CONTEXT AND CAVEATS

Prior knowledge
The National Cancer Institute of Canada Clinical Trials Group CO.17 study is a randomized study of the epidermal growth factor receptor -targeting antibody cetuximab vs best supportive care among patients with advanced colorectal cancer that showed improved overall survival with cetuximab. The survival advantage was higher for patients whose tumors harbored wild-type KRAS .
Study design
A cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received cetuximab or best supportive care. Mean survival times of the study arms for the entire study population and for patients whose tumors harbored wild-type KRAS were calculated over an 18-to 19-month period.
Contribution
For all patients in the CO.17 trial, cetuximab showed very high incremental cost-effectiveness ratios (cost per life-year gained and cost per quality-adjusted life-year gained) when compared with best supportive care. The incremental cost-effectiveness ratios were more favorable for patients whose tumors harbored wildtype KRAS but still in excess of $120 000 per life-year gained and $186 000 per quality-adjusted life-year gained.
Implications
Providing cetuximab only to patients with tumors that express wild-type KRAS has a more favorable cost-effectiveness ratio than treating patients irrespective of tumor KRAS mutation status but still has a high cost-effectiveness ratio.
Limitations
The results may not be generalizable to all patients under routine care for advanced colorectal cancer. The maximum follow-up in the trial was 1.58 years. The CO.17 trial included patients who had chemorefractory disease, but this is an approved indication for cetuximab.
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Methods
Study Parameters
CO.17 was conducted by the NCIC CTG in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG) (December 2003 to August 2005 . Funding for the trial was provided by the NCIC CTG, the AGITG, Bristol-Myers Squibb, and ImClone Systems Incorporated. The trial database was maintained by NCIC CTG. Approval for the conduct of the trial, including the collection of resource utilization data and health preference utilities, was cost -utility ratio was $186 761 per QALY gained (95% CI = $130 326 to $334 940 per QALY gained). In a sensitivity analysis, cetuximab cost and patient survival were the only variables that influenced costeffectiveness.
granted by the research ethics board of each participating institution. All patients provided written informed consent. The results of all study patients (Canadian and Australian) were used in this analysis.
A total of 572 patients with chemorefractory colorectal cancer were randomly assigned to receive cetuximab (an initial intravenous dose of 400 mg/m 2 of body surface area, followed by a weekly infusion of 250 mg/m 2 ) plus best supportive care (N = 287) or best supportive care alone (N = 285). Treatment was continued until the occurrence of unacceptable adverse events, tumor progression, worsening symptoms of the cancer, patient request (with or without the withdrawal of consent for continued follow-up), or death. The median duration of cetuximab treatment was 8.1 weeks (range = 1 -60 weeks). The primary endpoint was overall survival and the secondary endpoint was progression-free survival. The median age of patients in the cetuximab group was 63.0 years (range = 28.6 -88.1 years) and in the best supportive care group, 63.6 years (range = 28.7 -85.9 years). A total of 368 patients (64%) were male. The majority of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 1. Nearly 60% of the patients had been diagnosed with colon cancer only. All patients who underwent random assignment were included in the effi cacy analyses.
Economic Parameters
This economic evaluation was conducted from the perspective of the payer (ie, the Canadian government) as required by decision makers for cost-effectiveness analyses. Cetuximab was compared with best supportive care because, at the time of the trial, there were no other standard chemotherapy options available for these patients. The choice of best supportive care is consistent with economic evaluation guidelines that recommend using the standard intervention as the comparator agent ( 18 ) .
Determination of Direct Medical Costs
Costs are presented in 2007 Canadian dollars (Can $1 = US $1). Costs not available in 2007 Canadian dollars were adjusted for inflation by using the consumer price index ( http :// bankofcanada . ca / en / cpi . html ).
Cost of Drugs. The cost of cetuximab in 2005 ranged from $2.94 to $6.73/mg in countries that were reviewed by the Patented Medicine Prices Review Board ( 19 ) . The base case cost used for this study was $3.24/mg and represented the median cost of the drug among these countries.
Cost of Outpatient Visits. The number of outpatient clinic visits was recorded. The cost of an outpatient physician assessment was based on the Ontario Health Insurance Plan (OHIP) fee schedule ( 20 ) and recorded according to the specific type of assessment performed (consultation, general assessment, or partial assessment). The cost of an outpatient chemotherapy visit was determined from the amount of time spent by a nurse for patient education and counseling and infusion chemotherapy administration time and the average 2007 salary levels for nursing and supportive care staff at one study site (Sunnybrook Health Sciences Centre, Ontario, Canada) ( 21 ) .
Cost of Hospitalization and Surgical Procedures. The location(s) where care was provided (general hospital ward, oncology ward, intensive care unit, and/or rehabilitation facility) was recorded. A per diem cost for the appropriate care unit was obtained from one study site (Sunnybrook Health Sciences Centre) and multiplied by length of stay for each patient ( 21 ) .
Cost of Adverse Events. Only grades 3 and 4 adverse events were included because less severe adverse events would not be associated with substantial use of health-care resources. Adverse events included in this analysis were rash, non-neutropenic infections, and pain. These events differed statistically significantly between treatment groups. Confusion was not included even though it differed statistically significantly between treatment groups because resources for its management were unclear. Treatment protocols for each adverse event were standardized based on expert opinion. Hospital costs, based on the Ontario Case Costing Initiative ( 22 ) , were applied to the corresponding adverse event International Classification of Diseases, Tenth Revision diagnostic code ( 23 ) .
Cost of Laboratory Tests and Diagnostic Procedures.
The number and type of laboratory and radiologic tests and procedures conducted during the trial were extracted from the trial database. Laboratory costs and diagnostic procedure costs were based on the 2007 OHIP fee schedule ( 20 ) .
Other Costs. All emergency department visits and blood transfusions during the trial were recorded. Institutional costs were applied to emergency department visits and blood transfusion costs (calculated as the number of units of blood product transfused multiplied by the per-unit cost of the blood product) ( 24 ) . Nonmedical costs (both direct and indirect) were not included in this analysis.
Cost of Radiation Treatment. The use of palliative radiotherapy did not differ between the two treatment arms and therefore its cost was not included in this analysis.
Cost of KRAS Mutation Screening. All patients with available paraffin-embedded tumor tissue samples were screened for the KRAS mutation status of their tumor. Thus, the cost of KRAS mutation screening did not differ between the treatment arms and was not included in this analysis.
Determination of Outcomes
The overall direct medical costs for each patient in each study arm were estimated as the sum of the medical costs listed above. The treatment benefit was defined as the mean survival gain after random assignment. We defined treatment benefit in terms of mean survival rather than in terms of median survival because it allowed us to perform the required arithmetic manipulation of incremental survival duration to derive the incremental cost-effectiveness ratio. We used two methods to calculate overall survival: the restricted mean survival method, which restricts calculation of mean survival to the longest observed survival time (ie, the horizon of the trial), and the Kaplan -Meier method, which takes into account the survival times of censored patients (including those still alive at the end of the study) ( 25 ) .
Determination of QALYs
The self-reported Health Utility Index Mark 3 (HUI3) was prospectively collected to assess preference-based measures of health status throughout the study (ie, at random assignment [baseline] and at 4 weeks, 8 weeks, 16 weeks, and 24 weeks after random assignment) ( 26 ) . Questions in the HUI3 cover the following eight health attributes: vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain. At each assessment time, patients rated their health attributes. An overall utility score was calculated based on the answers to these questions and weighted using the HUI formula according to values derived from the general Canadian population. Utility values in the HUI3 range from 0 (death) to 1 (perfect health). The number of QALYs for each patient was calculated based on the utility scores at each assessment time multiplied by follow-up time interval. The area under the curve was used to determine the mean survival ( 27 ) . For patients who did not have a utility score (ie, censored patients), the last utility observation was carried forward.
Time Horizon
The time horizon of the analysis was the duration of the clinical trial (ie, 18 -19 months) because more than 77% of the patients on cetuximab and 82% of those on best supportive care alone had died by the end of the data collection period. Because the median survival time in the study was less than 1 year, discounting was not used.
Base Case Analysis
In the base case analysis, each unit cost was multiplied by the resources used on a per-patient basis. The incremental ratios of the differences in mean costs, survival, and QALYs between the cetuximab arm and the best supportive care arm were determined for the entire study population and for the patients whose tumors harbored wild-type KRAS . Results are presented as the cost per life-year gained and the cost per QALY gained.
Sensitivity Analyses
We performed one-way deterministic sensitivity analyses to test the robustness of the incremental ratios. In these analyses, the cost of cetuximab was varied from $2.94 (Switzerland) to $6.73 (United States) per mg to reflect the international cost of the drug ( 19 ) . Survival was varied from +20% to -20% of the original base case value. In addition, between-country heterogeneity was examined. The 95% confidence intervals (CIs) for the incremental costeffectiveness ratios and the incremental cost -utility ratios were estimated by use of a nonparametric bootstrapping method (with 1000 iterations). Uncertainty surrounding the estimates of costeffectiveness was illustrated by means of cost-effectiveness acceptability curves, which depict the probability that an intervention is cost-effective when compared with an alternative (either another intervention or no intervention) for a range of incremental costeffectiveness ratios.
Results
Patient Demographics
Five hundred seventy-two patients were accrued to CO.17 (287 to cetuximab). All patients had received prior chemotherapy with a fluoropyrimidine; 98% of patients had received prior treatment with oxaliplatin and 96% had received prior treatment with irinotecan. The KRAS mutation status of the tumor was determined retrospectively for 394 patients (69%; 198 from the cetuximab group and 196 from the best supportive care group); 58% of the tumors had wild-type KRAS (117 from the cetuximab group and 113 from the best supportive care group) ( 7 ).
HUI Values
HUI3 values for cetuximab and for best supportive care were recorded over the duration of the trial ( Table 1 ) . At each follow-up, mean utility scores for cetuximab were higher than those for best supportive care. For the cetuximab arm, the utility scores remained essentially unchanged at each follow-up. By contrast, utility scores for best supportive care generally declined with time. However, direct interpretation of utility scores is difficult because of survivorship bias as observed by the high utility scores in the last follow-up.
Costs and Economic Analysis for the Entire Study Population
Costs, resources, and cost source information are presented in Table 2 . Total costs were higher in the cetuximab arm than in the best supportive care arm, with the incremental cost with cetuximab calculated at $23 969 per patient ( Table 3 ). The mean survival gain with cetuximab was 0.12 years (7.7 months [0.64 years] in the cetuximab arm vs 6.2 months [0.52 years] in the best supportive care arm). The gain in survival for cetuximab compared with best supportive care resulted in a mean incremental cost-effectiveness ratio of $199 742 per life-year gained (95% CI based on the bootstrap analysis = $125 973 to $652 492 per life-year gained) ( Figure 1 , A , Table 4 ). Cetuximab resulted in a mean gain of 0.08 QALYs, with a mean incremental cost -utility ratio of $299 613 per QALY gained (95% CI based on the bootstrap analysis = $187 400 to $898 201 per QALY gained) ( Figure 1 , B , Table 4 ).
Economic Analysis for the Subset of Patients With WildType KRAS Tumors
For the patients whose tumors harbored wild-type KRAS , total costs were higher in the cetuximab arm than in the best supportive care arm, with the incremental cost with cetuximab calculated at $33 617 per patient ( Figure 2 , A , Table 4 ). The mean survival gain with cetuximab increased to 0.28 years (9.5 months [0.79 years] in the cetuximab vs 6.1 months [0.51 years] in the best supportive care arm). This gain in survival resulted in a mean incremental cost-effectiveness ratio of $120 061 per life-year gained (95% CI ( 20 ) * ALK phos = alkaline phosphatase; ALT = alanine transaminase; ASA = acetylsalicylic acid; AST = aspartate aminotransferase; CBC = complete blood count; IU = international unit; LDH = lactate dehydrogenase; MS = morphine sulphate; NSAID = nonsteroidal anti-inflammatory drug; OCCI = Ontario Case Cost Initiative; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; PMPRB = Patented Medicines Prices Review Board; SR = sustained release. † Unit cost includes a dispensing fee that was assumed to be $10.
based on the bootstrap analysis = $88 679 to $207 075 per life-year gained) ( Figure 2 , A , Table 4 ). The mean number of QALYs gained for cetuximab in this subset analysis was 0.18, with a mean incremental cost -utility ratio of $186 761 per QALY gained (95% CI based on the bootstrap analysis = $130 326 to $334 940 per QALY gained) ( Figure 2 , B , Table 4 ).
Sensitivity Analysis
The incremental cost-effectiveness ratios were most sensitive to changes in the cost of cetuximab and patient survival ( Table 5 ) . A sensitivity analysis was performed on every cost, resource, and effectiveness variable. The cost of cetuximab and patient survival were the only variables that were found to influence cost-effectiveness.
The remaining variables had minimal impact on the incremental ratios (data not shown). There was no evidence of heterogeneity between countries (data not shown). For the entire study population, the probability of cetuximab being considered cost-effective was 0% at a threshold value of $50 000 per life-year gained, 0.1% at a threshold value of $100 000 per life-year gained, and 43.4% at a threshold value of $200 000 per life-year gained ( Figure 1, C ) . In the cost-per-QALY case, the probability that cetuximab is cost-effective compared with best supportive care in the entire population is 0 for thresholds of $150 000 per QALY or less ( Figure 1, D ) . At a threshold of $200 000 per QALY, there is only a 3.4% chance that cetuximab is cost-effective compared with best supportive care. For the wild-type KRAS tumor population, the probability of cetuximab being considered costeffective was 0% at a threshold value of $50 000 per life-year gained, 9.3% at a threshold value of $100 000 per life-year gained, and 96.6% at a threshold value of $200 000 per life-year gained ( Figure  2, C ) . Similarly, at thresholds of $100 000 and $200 000 per QALY, the probabilities of cost-effectiveness for cetuximab compared with best supportive care are 0% and 61%, respectively ( Figure 2, D ) .
Discussion
The NCIC CTG CO.17 trial is a landmark study that showed a statistically significant survival gain in patients with advanced metastatic colorectal cancer receiving cetuximab. In this economic analysis, cetuximab showed high incremental cost-effectiveness ratios when compared with best supportive care for all patients in the CO.17 trial. The incremental cost-effectiveness ratios were lower for patients with wild-type KRAS tumors, suggesting that providing cetuximab only to patients with wild-type KRAS may avoid the health-care system costs of using an expensive drug that would provide little or no clinical benefit to treat patients whose tumors do not express wild-type KRAS .
To our knowledge, this economic evaluation of the NCIC CTG CO.17 trial is the fi rst large-scale analysis from an oncology cooperative group that has collected resource utilization and utility values prospectively in an international phase III clinical trial ( 4 ) . By using actual trial data, we avoided having to make assumptions about resource utilization that are often required in economic analyses that use models.
The mean incremental cost-effectiveness ratio of cetuximab compared with best supportive care for patients with wild-type KRAS tumors was lower and had narrower 95% confi dence intervals than that for all CO.17 patients regardless of tumor KRAS mutation status , even though the incremental ratios remained high. The decrease in the incremental cost-effectiveness ratios for the subanalysis of patients with wild-type KRAS tumors was driven primarily by longer survival in the cetuximab group.
The clinical benefi t from targeted therapies in oncology is limited to a subgroup of patients, but biomarkers for prospective selection of these patients have previously been lacking. The tumor mutation status of the KRAS oncogene has been investigated as a predictor of clinical outcomes ( 7 -13 ) . The cost-effectiveness of cetuximab compared with best supportive care for the subset of the population with wild-type KRAS tumor status may actually be even more favorable (ie, the cost-effectiveness ratios may be lower) than that calculated in this analysis because the survival curves for patients with wild-type KRAS tumors and for those with mutant KRAS tumors had not yet converged at the end of the trial ( 7 ), which indicates an even greater survival advantage for the wild-type KRAS tumor populations treated with cetuximab. However, the cost-effectiveness acceptability curves showed that there was a 0% probability of the threshold falling below $50 000 per life-year gained or below $50 000 per QALY gained for the wild-type KRAS tumor population.
With respect to survival, the increased clinical benefi t of cetuximab compared with best supportive care alone in patients with wild-type KRAS tumors may encourage the routine clinical testing for KRAS mutations in tumors from patients with metastatic colorectal cancer. It is important to note that we did not include the cost of KRAS mutation testing ( ~ $300 -$600 per test) in this trialbased economic analysis because within this study, the cost of testing was applied to both cetuximab and best supportive care patients in the wild-type KRAS subset analysis. Thus, the incremental cost-effectiveness ratios were unlikely to have been affected by including the cost of KRAS mutation testing.
Economic evaluations should identify subgroups for which there is evidence for increased effectiveness of an intervention. A policy of treating the estimated 40% of patients whose tumors harbor mutated KRAS ( 7 , 16 , 17 ) with best supportive care alone would avoid the health-care costs of using cetuximab, an expensive drug from which this group of patients can expect little or no benefi t. A recently published abstract from the US perspective reported a cost savings of $600 million associated with treating only the colorectal cancer patients whose metastatic tumors harbor wild-type KRAS with cetuximab ( 31 ) . It is important for health-care payers to be informed about the fi nancial impact and clinical benefi ts of a strategy of providing cetuximab only to patients with wild-type KRAS compared with providing best supportive care alone regardless of KRAS mutation status. This economic analysis evaluated the cost-effectiveness of the CO.17 trial population, which includes a subpopulation with wild-type KRAS tumors. This analysis is not an economic analysis of KRAS screening. An assessment of KRAS screening would require a separate analysis. We note that cetuximab is not yet reimbursed by the public payers in either of the two countries in which this clinical trial was conducted.
KRAS mutation analysis showed that treatment with cetuximab increases the survival advantage in a group of patients that can be selected as more likely to benefi t from this treatment. Whether the incremental cost-effectiveness ratio continues to remain higher than what most payers are willing to pay speaks to the issue of what is considered an acceptable threshold and is currently being debated.
The health utility values obtained in the trial are similar to those reported in other studies. For example, in a survey of health-related quality of life among a community-based sample of individuals with colorectal carcinoma, Ramsey et al. ( 32 ) stratifi ed colorectal patients by stages and time since diagnosis and reported that patients with stage IV colorectal cancer had a mean utility value of 0.84. This value is higher than any of the utility values in either treatment arm of CO.17. It is important to emphasize that this analysis used utilities that were measured with the HUI3 and were obtained directly from patients in the CO.17 trial. Thus, it is possible that the utility values used in this study may not refl ect general population preferences for health states ( 26 ) . Considerable debate remains as to whose preference valuation, namely society's, patients ' , patients ' families ' , and/or health-care professionals ' , should be considered in economic decision analyses ( 33 , 34 ) . This study has fi ve possible limitations. First, results of this analysis are based on clinical trial results and thus may not be generalizable to routine care. Second, the time horizon for the analysis was trial driven, and the maximum follow-up was between 18 and 19 months (1.58 years; the last point on the survival curve). However, given the advanced stage of the colorectal cancers and the short survival of patients on CO.17, it is unlikely that there would be any statistically signifi cant survival gain beyond the trial duration for the overall population, but survival gain may be more important in the wild-type KRAS subset because these patients demonstrated better clinical outcomes than the rest of the population. Third, it is important to note that the CO.17 trial included patients who had chemorefractory disease, which is also the approved indication for cetuximab ( 35 ) . Fourth, the study population was a selected group of patients with prior chemotherapy who still maintained a reasonable performance status (ie, ECOG 0 -2). Many heavily pretreated patients with advanced colorectal cancer have a poor performance status , and the results of this study may not be generalizable to very ill patients. Fifth, the end of the trial occurred when the proportion alive was less than 10%. Therefore, modeling beyond the end of the trial may be uninformative, making this analysis essentially a lifetime cost -utility analysis. It is important to note that, as per CO.17 protocol, patients received cetuximab until they experienced disease progression or they no longer derived clinical benefi t from therapy. Therefore, theoretically, patients could have received cetuximab in perpetuity. However, because less than 10% of the patients were alive at the end of the study time horizon, the decision to not model over a lifetime time horizon would not infl uence the economic outcome.
A determination of country-specifi c cost-effectiveness is important for health-care decision makers. The results of economic analyses based on multinational clinical trials may be subject to jurisdictional or geographical differences in patient population, clinical practice, and costs of resources ( 36 -38 ) . Possible heterogeneity in between-country data may limit the geographical transferability of pharmacoeconomic data. A number of methods (simple and complex) are available to adjust for the multinational nature of resource and survival data.
The cost of cetuximab was a major cost driver in this economic analysis. Cetuximab costs approximately twice as much in the United States as it does in Europe ( 19 ) . Using a US cost ($6.73/mg) resulted in a doubling of the incremental ratios. Survival was also a major cost driver in this economic analysis, and limiting cetuximab therapy to those who had the greatest survival benefi t (ie, those with wild-type KRAS tumors) improved the incremental cost-effectiveness ratio. However, not all costs were included in the economic evaluation; specifi cally, nonmedical and indirect costs were excluded. The incremental cost-effectiveness ratio was not sensitive to any cost variable except the cost of cetuximab.
The incremental cost-effectiveness ratios presented here represent the undiscounted ratios. In Canada, a 5% discount rate is used in economic analyses ( 18 ) . A discount rate was not applied to this analysis because the median survival of study subjects was less than 1 year and utility values were only collected over a 28-week period. Thus, we felt that discounting was unlikely to have a large impact because of the short survival of this patient group.
The economic burden of colorectal cancer is substantial ( 39 , 40 ) . The cost of new targeted therapies for this and other cancers has received much attention ( 41 , 42 ) . Norum ( 43 ) modeled irinotecan plus cetuximab vs no chemotherapy in patients with metastatic colorectal cancer in Norway and estimated incremental cost-effectiveness ratios ranging from € 205 536 to € 323 040 per life-year gained ( € 1 = US $1.59). Starling et al. ( 44 ) also analyzed cetuximab plus irinotecan vs active plus best supportive care in the United Kingdom and estimated incremental cost-effectiveness ratios of £42 975 per life-year gained and £57 608 per QALY (£1 = US $2). The incremental benefi t for cetuximab in our study was smaller than either of these two studies. These studies, however, did not assess the effect of the tumor KRAS mutation status on the incremental cost-effectiveness.
Economic analyses are conducted to provide decision makers with information on the costs and clinical benefi ts of specifi c interventions. A number of jurisdictions, including Canada, the United Kingdom, Scotland, and Australia, require formal economic evaluations for drug reimbursement. It has been suggested that as the incremental cost-effectiveness ratio increases, the probability of reimbursement decreases ( 45 ) . Decisions regarding reimbursement are complex and involve many factors including affordability, burden of disease, improvement in survival, availability of alternatives, quality of life, and cost-effectiveness ( 46 ) .
Cost-effectiveness analysis has been increasingly used as a measure to inform treatment allocation in a shrinking health-care resource environment. The National Institute for Health and Clinical Excellence guidelines recommend considering factors in addition to cost-effectiveness for interventions that have incremental cost-effectiveness ratios greater than £30 000 per QALY (£1 = US $2) ( 45 , 47 ) . In the United States, a benchmark threshold of approximately $50 000 per QALY exists. In the United Kingdom, a threshold of £30 000 per QALY has been applied ( 48 , 49 ) . A survey of health economists found a threshold of $60 000 per QALY to be acceptable ( 50 ) . Where thresholds have been suggested, they have not been focused on classes of drugs. However, a 2006 survey of medical oncologists inferred a $300 000-per-QALY threshold for oncology medications ( 51 ) . It is important to note that there is no empirical evidence to support a particular threshold value. Most jurisdictions have implicit thresholds ( 52 ) , but threshold values may not be formally declared if the setting of a threshold is value driven and may be politically sensitive ( 45 ) .
Our incremental cost-effectiveness ratio for cetuximab of $199 742 per life-year gained is considerably higher than the jurisdictional thresholds of which we are aware. However, restricting cetuximab to patients with wild-type KRAS tumors reduced the incremental cost-effectiveness ratio to $120 061, indicating that the use of cetuximab only in this group of patients would result in a more effi cient use of health-care resources. Although the wildtype KRAS group had a greater survival gain with cetuximab vs best supportive care (3 -4 months = 0.25 -0.33 years) compared with the overall group (1.5 months = 0.13 years), the drug cost was also greater in the wild-type KRAS group because cetuximab was used for a longer time. However, the incremental cost-effectiveness ratio was still high for the wild-type KRAS group and would generally be considered unfavorable. To achieve a generally accepted level of cost-effectiveness, we hypothesize that the survival gain would need to be on the order of 6 -8 months, even allowing for longer drug use. The cost-effectiveness acceptability curves revealed a 100% probability that cetuximab is not cost-effective compared with best supportive care above a threshold incremental cost-effectiveness ratio of $50 000 per QALY for both the entire population and the wild-type KRAS tumor subset.
Recent trials with cetuximab have shown statistically signifi cant improvement in survival over best supportive care in metastatic colorectal cancer patients ( 3 -5 ) . Additional trials have reported increased survival benefi ts in the wild-type KRAS tumor population ( 6 , 7 ) . Consequently, from a health-care system perspective, it would not be effi cient to fund cetuximab treatment for all patients with advanced colorectal cancer ( 7 ) . Use of cetuximab may be restricted based on a patient's tumor KRAS status ( 53 ) .
